Optinose Reports First Quarter 2021 Financial Results and Operational Updates
Published: May 05, 2021 Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- OptiNose AS (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2021, and provided operational updates. “XHANCE net revenues increased 55% in the first q...